Shane Schaffer, the Co-founder, Chairman, and CEO of Cingulate Therapeutics in Kansas City, Kansas, leads a Phase 3 clinical-stage biopharmaceutical company at the forefront of developing and managing branded, next-generation pharmaceutical products. Specializing in Attention Deficit/Hyperactivity Disorders (ADHD), the company also tackles therapeutic areas like anxiety disorders and insomnia. With a robust 25-year background in the pharmaceutical industry, Dr. Schaffer is renowned for his drug development and commercialization expertise. His leadership is characterized by thoughtful decision-making and an entrepreneurial spirit. He is pivotal in product launches, brand planning, joint venture brand management, life cycle management, and market development, earning him a notable reputation in biopharmaceutical and marketing. After obtaining his doctoral degree in Pharmacy from the University of Kansas in 1999, he advanced his training at Rutgers University's College of Pharmacy, where he undertook a postdoctoral pharmaceutical industry fellowship. He worked at Pfizer Worldwide Marketing and Morris Plains during this period, enhancing his strategic marketing and communication skills. While at Pfizer Worldwide Marketing in New York, he assumed the role of Marketing Manager, developing pre-launch strategies and initiating the Global Communications Intranet to foster effective communication between medical and marketing stakeholders. He also contributed to creating and implementing the Pfizer Medical and Academic Partnership in Pain Management. At Morris Plains in New Jersey, he was a Project Manager and External Research Manager, where he led advanced sales training and managed Phase IV Medical Research for all marketed brands. These roles underscored his ability to lead and strategize effectively within the industry. Throughout his career, Dr. Schaffer held multiple managerial positions at Pfizer, Novartis, and Sanofi, where he was instrumental in developing and commercializing several billion-dollar brands. At Novartis, he managed the Ritalin® LA / Focalin™ segments, successfully launching these products and achieving significant market penetration and brand awareness. His subsequent role at Sanofi allowed him to continue positively impacting the industry. He was involved in key initiatives during the company’s merger and joint venture phases. His efforts in professional promotion managed care marketing strategy, and salesforce execution played a crucial role in the success of brands like Avapro and Avalide. In 2008, he joined M|C Communications LLC in Boston as a consultant, leading the development of business opportunities for primary pharmaceutical targets. In July 2009, he founded Sabre Scientific Solutions, LLC, which provided consulting services to pharmaceutical and biotechnology companies in commercials, clinical strategies, LCM, product launches, and leadership. Driven by a passion for ADHD and its comprehensive treatment, Dr. Schaffer established Cingulate Therapeutics LLC in January 2013, focusing on innovative drug-delivery technologies for ADHD and anxiety disorders. This initiative reflects his ongoing commitment to enhancing patient care through advanced therapeutic solutions. Beyond his corporate responsibilities, Shane Schaffer is actively involved in philanthropy, notably with the Folds of Honor Charity, which provides educational scholarships to children of fallen or disabled military personnel. His extensive professional experience and philanthropic efforts illustrate his profound impact on the healthcare industry and community welfare.